Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-02-26 Sale |
2024-02-28 5:14 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $16.89 | $202,653 | 1,537,137 (Indirect Direct) |
View |
| 2024-02-15 Sale |
2024-02-20 7:41 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $17.42 | $22,117 | 211,363 (Indirect Direct) |
View |
| 2024-02-14 Sale |
2024-02-16 4:15 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
825,000 | $14.9 | $12,292,500 | 635,341 (Indirect) |
View |
| 2024-02-06 Sale |
2024-02-08 8:47 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $15.11 | $73,658 | 406,374 (Indirect Direct) |
View |
| 2024-01-31 Sale |
2024-02-02 4:29 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
500,000 | $15 | $7,500,000 | 771,983 (Indirect) |
View |
| 2024-01-30 Sale |
2024-02-01 8:10 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $16.41 | $20,840 | 212,633 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 9:22 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $15.85 | $190,256 | 1,401,585 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 9:20 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $15.81 | $51,388 | 245,870 (Direct) |
View |
| 2024-01-25 Sale |
2024-01-29 8:01 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $15.69 | $188,229 | 1,549,137 (Indirect Direct) |
View |
| 2024-01-22 Sale |
2024-01-24 6:38 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
4,875 | $15.13 | $73,783 | 411,249 (Indirect Direct) |
View |
| 2023-12-29 Sale |
2024-01-03 7:01 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $14.28 | $171,381 | 1,413,585 (Indirect Direct) |
View |
| 2023-12-28 Sale |
2024-01-02 8:00 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
13,540 | $15.02 | $203,348 | 416,124 (Indirect Direct) |
View |
| 2023-12-28 Sale |
2024-01-02 7:59 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
11,870 | $15.02 | $178,327 | 766,146 (Direct) |
View |
| 2023-12-26 Sale |
2023-12-28 4:29 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $14.64 | $175,709 | 1,561,137 (Indirect Direct) |
View |
| 2023-12-22 Sale |
2023-12-27 5:28 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
1,085 | $15.03 | $16,306 | 429,664 (Indirect Direct) |
View |
| 2023-12-22 Sale |
2023-12-27 5:26 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
1,130 | $15.07 | $17,025 | 522,080 (Direct) |
View |
| 2023-12-21 Sale |
2023-12-26 7:32 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
6,566 | $13.07 | $85,790 | 1,740,681 (Indirect Direct) |
View |
| 2023-12-21 Sale |
2023-12-26 7:31 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,195 | $13.05 | $106,915 | 1,889,862 (Indirect Direct) |
View |
| 2023-12-21 Sale |
2023-12-26 7:29 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
216 | $13 | $2,808 | 213,903 (Indirect Direct) |
View |
| 2023-12-20 Sale |
2023-12-21 4:31 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
7,779 | $13.01 | $101,238 | 1,581,332 (Indirect Direct) |
View |
| 2023-12-19 Sale |
2023-12-21 4:29 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,888 | $13.01 | $115,646 | 1,755,955 (Indirect Direct) |
View |
| 2023-12-19 Sale |
2023-12-21 4:28 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
4,280 | $13.02 | $55,727 | 214,119 (Indirect Direct) |
View |
| 2023-11-03 Sale |
2023-11-06 4:43 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,546 | $13.08 | $111,751 | 1,441,039 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-02-26 Exercise |
2024-02-28 5:14 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $0 | 1,537,137 (Direct) |
View |
| 2024-02-26 Exercise |
2024-02-28 5:14 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $1.12 | 1,537,137 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:35 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:32 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
29,205 | $0 | 29,205 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:30 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:27 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:26 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award(A) |
2024-02-20 7:24 pm |
N/A 2034-02-13 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
23,364 | $0 | 23,364 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 9:04 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 9:02 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 9:00 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:56 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
410,000 | $0 | 410,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:54 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:52 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
21,043 | $0 | 21,043 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:50 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:48 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:46 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
185,000 | $0 | 185,000 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:44 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-02-13 Option Award |
2024-02-15 8:41 pm |
N/A 2034-02-12 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
16,835 | $0 | 16,835 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:22 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $0 | 1,401,585 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:22 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $1.12 | 1,401,585 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:20 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 245,870 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:20 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 245,870 (Direct) |
View |
| 2024-01-25 Exercise |
2024-01-29 8:01 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $0 | 1,549,137 (Direct) |
View |
| 2024-01-25 Exercise |
2024-01-29 8:01 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $1.12 | 1,549,137 (Direct) |
View |
| 2023-12-29 Exercise |
2024-01-03 7:01 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $0 | 1,413,585 (Direct) |
View |
| 2023-12-29 Exercise |
2024-01-03 7:01 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $1.12 | 1,413,585 (Direct) |
View |
| 2023-12-28 Exercise |
2024-01-02 7:59 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
11,870 | $0 | 766,146 (Direct) |
View |
| 2023-12-28 Exercise |
2024-01-02 7:59 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
11,870 | $2.48 | 766,146 (Direct) |
View |
| 2023-12-26 Exercise |
2023-12-28 4:29 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $0 | 1,561,137 (Direct) |
View |
| 2023-12-26 Exercise |
2023-12-28 4:29 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $1.12 | 1,561,137 (Direct) |
View |
| 2023-12-22 Exercise |
2023-12-27 5:26 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
1,130 | $0 | 522,080 (Direct) |
View |
| 2023-12-22 Exercise |
2023-12-27 5:26 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
1,130 | $2.48 | 522,080 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:32 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
6,566 | $0 | 1,740,681 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:32 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
6,566 | $1.12 | 1,740,681 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:31 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,195 | $0 | 1,889,862 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,195 | $1.12 | 1,889,862 (Direct) |
View |
| 2023-12-20 Exercise |
2023-12-21 4:31 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
7,779 | $0 | 1,581,332 (Direct) |
View |
| 2023-12-20 Exercise |
2023-12-21 4:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
7,779 | $1.12 | 1,581,332 (Direct) |
View |
| 2023-12-19 Exercise |
2023-12-21 4:29 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,888 | $0 | 1,755,955 (Direct) |
View |
| 2023-12-19 Exercise |
2023-12-21 4:29 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,888 | $1.12 | 1,755,955 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:43 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,546 | $0 | 1,441,039 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:43 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,546 | $1.12 | 1,441,039 (Direct) |
View |